NDUFAF6

Most people will never hear about this gene from their primary care doctor, yet variants in and around it have been tied to one of the most feared diseases of aging: Alzheimer's. Large genome-wide studies have identified NDUFAF6 (NADH:ubiquinone oxidoreductase complex assembly factor 6) as a late-onset Alzheimer's disease risk locus across multiple populations.

Rare inherited changes in this same gene cause severe childhood mitochondrial diseases. Knowing your genotype gives you a piece of the puzzle that standard cholesterol, glucose, and blood pressure tests cannot reveal.

What This Gene Does

NDUFAF6 (also called C8ORF38) makes a protein that helps assemble mitochondrial respiratory chain complex I. Mitochondria are the energy-producing compartments inside your cells, and complex I is the first major step in turning food into usable cellular energy. When NDUFAF6 cannot do its job, complex I does not assemble correctly, mitochondrial respiration drops, and the inside of the mitochondria takes on abnormal shapes. Re-introducing a working copy of the gene in lab studies of human kidney and lung tissue restores normal function.

The gene therefore acts as a quiet quality controller for your cellular power supply. Different types of variants in it carry very different consequences: two damaging copies cause rare, severe disease in children, while common small-effect variants near the gene shift adult disease risk in subtle but measurable ways.

Rare Inherited Disease: Leigh Syndrome and Acadian Fanconi Syndrome

When a person inherits two damaging copies of NDUFAF6, complex I assembly fails dramatically. Biallelic coding variants cause autosomal recessive Leigh syndrome, a severe early-onset neurodegenerative disorder driven by mitochondrial complex I deficiency. In a Japanese cohort of 166 genetically confirmed Leigh syndrome patients, those with NDUFAF6 deficiency had relatively milder symptoms and better survival than many other genetic subtypes, although the condition still typically appeared in childhood.

A specific non-coding intronic variant (c.298-768 T>C, rs575462405) causes the Acadian variant of Fanconi syndrome. The variant alters how NDUFAF6 is spliced in kidney and lung, producing complex I deficiency, proximal tubular dysfunction, chronic kidney disease, and pulmonary fibrosis. These are recessive conditions, meaning both inherited copies of the gene must be affected to cause disease.

Common Variants and Alzheimer's Disease Risk

More relevant for most adults is the link between common NDUFAF6 variants and late-onset Alzheimer's disease. Multiple large genome-wide and meta-analytic studies have flagged variants in or near this gene as Alzheimer's risk loci, including rs10098778 and rs4735340. An integrated genome and phenome study confirmed an Alzheimer's risk locus near NDUFAF6 among genetic signals also associated with platelet traits.

A cross-sectional population-based study of 5,096 Chinese rural older adults found that carrying two copies of the T variant at rs6982393 (TT genotype) raised Alzheimer's odds by roughly 60% compared with carrying one or no copies (odds ratio approximately 1.6 overall). The effect was strongest in adults aged 60 to 69. There was no association with milder cognitive impairment, suggesting the variant may matter most for the transition into clinical disease rather than for the earliest cognitive changes.

The risk compounded when combined with APOE ε4, the strongest known genetic risk factor for late-onset Alzheimer's. People carrying both the rs6982393 TT genotype and an APOE ε4 allele had higher odds than either alone, suggesting these two risk factors act together rather than canceling each other out.

A Possible Connection to Small Vessel Brain Disease

A study of 50 patients with cerebral small vessel disease, a condition that damages tiny blood vessels in the brain and contributes to stroke and cognitive decline, identified a heterozygous NDUFAF6 variant (p.Ala92Val) of uncertain significance in one case. The role of this gene in cerebral small vessel disease remains uncertain, but the finding fits the broader pattern that mitochondrial dysfunction may contribute to vascular brain aging.

Making Sense of Apparently Conflicting Signals

It may seem strange that one gene can cause devastating disease in some carriers and only mildly nudge risk in others. The resolution is that genetic variants are not all the same kind of thing. Two damaging copies that wreck the protein cause profound illness in childhood; common variants near the gene that subtly tune how much protein is made shift the long-term risk of age-related disease without causing it outright. The same gene, read differently, tells different stories. This test is best understood as a phenotype indicator that places you in a risk category, not as a yes-or-no verdict on whether you will develop a specific disease.

Why Genotype Is a Permanent Result, Not a Trend to Track

Unlike cholesterol or blood sugar, your genotype does not change over your lifetime. There is no point in retesting NDUFAF6 every year or after a lifestyle change. One accurate result is your result for life. What can change is the scientific understanding of what your variants mean. As research catches up with the genome, the same data file may yield richer interpretations. If you tested years ago, it is worth requesting a re-analysis of your variant data when you reach an age where Alzheimer's risk becomes more clinically relevant, typically your mid 50s and beyond.

The most useful longitudinal tracking happens elsewhere. If you carry higher-risk NDUFAF6 variants, the markers worth tracking over time are the ones that reflect brain and cardiovascular health: blood pressure, cholesterol, blood sugar, inflammation, and increasingly, plasma amyloid and phosphorylated tau biomarkers as those tests mature.

What to Do if Your Result Shows a Higher-Risk Variant

A genetic result of this kind is information, not a diagnosis. The decision pathway depends on the type of variant detected:

• Common Alzheimer-risk variant (e.g., rs6982393 TT): order APOE genotyping if not done. Track your blood pressure, lipid panel including ApoB, fasting insulin, HbA1c (hemoglobin A1c), and hs-CRP (high-sensitivity C-reactive protein) at least yearly. Consider plasma Amyloid Beta 42/40 and p-Tau217 testing if you are over 55 or have a family history of dementia.
• Heterozygous variant of uncertain significance: consult a genetic counselor before drawing conclusions. A single inherited copy of a coding change in this gene does not by itself cause mitochondrial disease, and most carriers remain healthy.
• Two damaging copies suggesting recessive disease: this is rare and would typically present clinically in childhood. Adult discovery of biallelic damaging variants should be reviewed by a clinical geneticist or mitochondrial disease specialist.

When Results Can Be Misleading

Genetic testing is highly accurate at reading what the DNA says, but interpretation is where errors creep in. Studies show that clinicians and testing labs disagree on how to classify a variant about 13% to 18% of the time, often in ways that would change management. Common pitfalls to watch for:

• Variant of uncertain significance (VUS): the change in your DNA is real, but not enough is known yet to say whether it affects health. A VUS is not the same as a positive result, and it should not drive aggressive action.
• Limited panels miss noncoding variants: the variant causing Acadian Fanconi syndrome sits in an intron, outside the protein-coding portion of the gene. Standard exome sequencing may not capture every important change in or near this gene.
• Population-specific variants: the rs6982393 finding came from a Chinese rural cohort. The size of the risk effect in other ancestries has not been confirmed by the same kind of study and may differ.
• False sense of security from a normal result: Alzheimer's disease is shaped by dozens of genetic and lifestyle factors. A reassuring NDUFAF6 result does not mean low overall risk.

If your report flags anything unusual, request the underlying variant data and ask a genetic counselor to review it with you. Reanalysis as the science evolves can change a VUS classification, sometimes years after the original test.